Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3N2v Vaccine in Healthy Adults and Elderly
NCT01746082Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2013
- Primary completion
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza A/H3N2 variant vaccine in influenza (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of subjects achieving seroconversion (HAI) at 21 days, Occurrence of solicited injection site and systemic reactogenicity at 7 days and 2 more. Started Jan 2013; status: completed.
02
Drugs
influenza A/H3N2 variant vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01746082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746082.